Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

Fig. 1

Randomization and follow-up. There were 183 patients randomized into the single-strength sulfamethoxazole-trimethoprim (SMX/TMP) dosage group (SS) (n = 62), half-strength dosage group (HS) (n = 61), and the escalation dosage group (ES) (n = 60). There were 4 patients in SS, 2 in HS, and 5 in ES who were found to be ineligible after randomization and were excluded. There were 58 patients in SS, 59 in HS, and 55 in ES who started treatment with SMX/TMP and met the definition of the full analysis set (FAS). Of these, in SS, HS, and ES, respectively, 2, 2, and 3 patients discontinued this study because of transfer to another hospital or death, and 24, 11, and 14 patients stopped or reduced SMX/TMP because of adverse events (AE), prescription error, or on the decision of the attending physician. D/C discontinued

Back to article page